Journal
BIOLOGICAL PSYCHIATRY
Volume 52, Issue 9, Pages 887-895Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0006-3223(02)01377-X
Keywords
PPI; P50 suppression; haloperidol; ketamine; sensory gating
Categories
Ask authors/readers for more resources
Background: Antagonists of the N-methyl-D-aspartate (NMDA) receptors induce a broad range of psychophysiologic symptoms in healthy subjects that are similar to those of schizophrenia, such as disturbances in the sensory gating of stimuli. Because antipsychotics reduce symptoms in schizophrenia, they may also reduce the effects of NMDA antagonists. Methods: In our study, a group of 18 healthy male volunteers was tested in prepulse inhibition (PPI) and P50 evoked potential paradigms during placebo-placebo, placebo-ketamine (.3 mg/kg; intravenous), and 2-mg haloperidol/.3 mg/kg intravenous ketamine conditions. Results: Suppression of PPI and P50 in the ketamine condition did not differ from either the placebo placebo or the haloperidol-ketamine condition; however, a significant reduction in percentage PPI to the lowest prepulse intensity and a reduction of P50 suppression were found in the haloperidol-ketamine condition. Conclusions: The combination of haloperidol and ketamine was found to disrupt P50 suppression and PPI in healthy male volunteers, whereas ketamine alone did not affect either measure. This may imply that the disrupted P50 suppression and PPI found in schizophrenia is related to reduced dopaminergic activity, most likely in the prefrontal cortex. (C) 2002 Society of Biological Psychiatry.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available